As of 2024-12-15, the Relative Valuation of Tarsus Pharmaceuticals, Inc. (TARS) is (84.86) USD. This relative valuation is based on P/E multiples. With the latest stock price at 52.50 USD, the upside of Tarsus Pharmaceuticals, Inc. based on Relative Valuation is -261.6%.
The range of the Relative Valuation is (78.64) - (87.99) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.4x - 25.0x | 23.2x |
| Forward P/E multiples | 22.4x - 26.2x | 25.2x |
| Fair Price | (78.64) - (87.99) | (84.86) |
| Upside | -249.8% - -267.6% | -261.6% |
| Date | P/E |
| 2024-12-06 | -14.74 |
| 2024-12-05 | -14.32 |
| 2024-12-04 | -14.70 |
| 2024-12-03 | -14.34 |
| 2024-12-02 | -14.35 |
| 2024-11-29 | -14.93 |
| 2024-11-27 | -14.47 |
| 2024-11-26 | -14.13 |
| 2024-11-25 | -13.75 |
| 2024-11-22 | -13.73 |
| 2024-11-21 | -13.20 |
| 2024-11-20 | -13.26 |
| 2024-11-19 | -13.34 |
| 2024-11-18 | -12.70 |
| 2024-11-15 | -12.76 |
| 2024-11-14 | -13.28 |
| 2024-11-13 | -13.23 |
| 2024-11-12 | -13.54 |
| 2024-11-11 | -13.97 |
| 2024-11-08 | -14.06 |
| 2024-11-07 | -13.32 |
| 2024-11-06 | -13.32 |
| 2024-11-05 | -12.99 |
| 2024-11-04 | -13.15 |
| 2024-11-01 | -13.46 |
| 2024-10-31 | -12.66 |
| 2024-10-30 | -12.73 |
| 2024-10-29 | -12.48 |
| 2024-10-28 | -11.29 |
| 2024-10-25 | -11.21 |
| 2024-10-24 | -11.07 |
| 2024-10-23 | -11.10 |
| 2024-10-22 | -10.81 |
| 2024-10-21 | -10.37 |
| 2024-10-18 | -10.42 |
| 2024-10-17 | -10.55 |
| 2024-10-16 | -10.70 |
| 2024-10-15 | -10.61 |
| 2024-10-14 | -10.38 |
| 2024-10-11 | -10.16 |
| 2024-10-10 | -10.10 |
| 2024-10-09 | -9.88 |
| 2024-10-08 | -9.68 |
| 2024-10-07 | -9.45 |
| 2024-10-04 | -9.64 |
| 2024-10-03 | -9.18 |
| 2024-10-02 | -9.32 |
| 2024-10-01 | -9.19 |
| 2024-09-30 | -9.36 |
| 2024-09-27 | -9.25 |